应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02142 和铂医药-B
已收盘 07-26 16:08:20
1.290
+0.030
+2.38%
最高
1.320
最低
1.280
成交量
64.60万
今开
1.300
昨收
1.260
日振幅
3.17%
总市值
9.92亿
流通市值
9.92亿
总股本
7.69亿
成交额
84.17万
换手率
0.08%
流通股本
7.69亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
和铂医药将在2024年欧洲肿瘤内科学会(ESMO)年会上展示全球首创靶向B7H7/HHLA2全人源单克隆抗体HBM1020的最新临床研究进展
美通社 · 10:05
和铂医药将在2024年欧洲肿瘤内科学会(ESMO)年会上展示全球首创靶向B7H7/HHLA2全人源单克隆抗体HBM1020的最新临床研究进展
和铂医药(02142.HK)预告上半年正面盈利,造血能力持续彰显
权证网 · 07-22
和铂医药(02142.HK)预告上半年正面盈利,造血能力持续彰显
港股异动 | 和铂医药-B(02142)盘中跌超6% 预计上半年溢利同比下滑约48.3%至65.5%
智通财经 · 07-19
港股异动 | 和铂医药-B(02142)盘中跌超6% 预计上半年溢利同比下滑约48.3%至65.5%
和铂医药-B(02142)下跌5.52%,报1.37元/股
金融界 · 07-19
和铂医药-B(02142)下跌5.52%,报1.37元/股
和铂医药-B盘中异动 股价大跌5.45%报1.371港元
自选股智能写手 · 07-19
和铂医药-B盘中异动 股价大跌5.45%报1.371港元
【公司盈警】和铂医药(02142)料中期溢利减少至100万-150万美元
金吾财讯 · 07-19
【公司盈警】和铂医药(02142)料中期溢利减少至100万-150万美元
《盈警》和铂医药(02142.HK)料上半年溢利按年减少48.3%至65.5%
阿斯达克财经 · 07-19
《盈警》和铂医药(02142.HK)料上半年溢利按年减少48.3%至65.5%
和铂医药-B发盈警 预计中期溢利约100万美元至150万美元
新浪港股 · 07-19
和铂医药-B发盈警 预计中期溢利约100万美元至150万美元
和铂医药发布2024年度上半年正面盈利预告
美通社 · 07-19
和铂医药发布2024年度上半年正面盈利预告
和铂医药:收入结构变动,预期上半年溢利100万-150万美元
界面 · 07-19
和铂医药:收入结构变动,预期上半年溢利100万-150万美元
和铂医药-B(02142)发盈警 预计中期溢利约100万美元至150万美元
智通财经 · 07-19
和铂医药-B(02142)发盈警 预计中期溢利约100万美元至150万美元
和铂医药-B(02142)上涨5.0%,报1.47元/股
金融界 · 07-17
和铂医药-B(02142)上涨5.0%,报1.47元/股
和铂医药-B盘中异动 下午盘大幅上涨5.00%报1.470港元
自选股智能写手 · 07-17
和铂医药-B盘中异动 下午盘大幅上涨5.00%报1.470港元
港股异动 | 和铂医药-B(02142)涨超3% 双特异性抗体新药在中国获批临床
智通财经 · 07-15
港股异动 | 和铂医药-B(02142)涨超3% 双特异性抗体新药在中国获批临床
和铂医药(02142)双特异性抗体新药在中国获批临床
智通财经 · 07-12
和铂医药(02142)双特异性抗体新药在中国获批临床
和铂医药宣布向国家药品监督管理局重新递交巴托利单抗治疗全身型重症肌无力的生物制品许可申请
美通社 · 06-27
和铂医药宣布向国家药品监督管理局重新递交巴托利单抗治疗全身型重症肌无力的生物制品许可申请
和铂医药-B(02142.HK):再次向NMPA提交巴托利单抗(HBM9161)的BLA
格隆汇资讯 · 06-27
和铂医药-B(02142.HK):再次向NMPA提交巴托利单抗(HBM9161)的BLA
和铂医药-B盘中异动 大幅上涨5.63%
自选股智能写手 · 06-24
和铂医药-B盘中异动 大幅上涨5.63%
和铂医药-B(02142):Albert R. Collinson获委任为薪酬委员会主席
智通财经网 · 06-21
和铂医药-B(02142):Albert R. Collinson获委任为薪酬委员会主席
和铂医药-B(02142)下跌6.02%,报1.25元/股
金融界 · 06-18
和铂医药-B(02142)下跌6.02%,报1.25元/股
公司概况
公司名称:
和铂医药-B
所属市场:
SEHK
上市日期:
--
主营业务:
和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品包括巴托利单抗,主要用于免疫性血小板减少症、甲状腺相关性眼病、重症肌无力、视神经脊髓炎谱系疾病等;以及特那西普,主要用于干眼病。此外,该公司还研究和开发肿瘤免疫产品管线,包括内部开发的新一代肿瘤免疫资产,针对治疗免疫沙漠型、免疫排斥型及炎症型肿瘤。
发行价格:
--
{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":1.29,"timestamp":1721981300027,"preClose":1.26,"halted":0,"volume":646000,"delay":0,"floatShares":768876410,"shares":768876410,"eps":0.24247439,"marketStatus":"已收盘","marketStatusCode":5,"change":0.03,"latestTime":"07-26 16:08:20","open":1.3,"high":1.32,"low":1.28,"amount":841690,"amplitude":0.031746,"askPrice":1.3,"askSize":1000,"bidPrice":1.29,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0.23419154384211843,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"listingDate":1607529600000,"adjPreClose":1.26,"openAndCloseTimeList":[[1721957400000,1721966400000],[1721970000000,1721980800000]],"volumeRatio":0.487768,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142/wiki","defaultTab":"wiki","newsList":[{"id":"2454351745","title":"和铂医药将在2024年欧洲肿瘤内科学会(ESMO)年会上展示全球首创靶向B7H7/HHLA2全人源单克隆抗体HBM1020的最新临床研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2454351745","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454351745?lang=zh_cn&edition=full","pubTime":"2024-07-26 10:05","pubTimestamp":1721959500,"startTime":"0","endTime":"0","summary":"HBM1020是全球首个正式获批进入临床阶段的靶向B7H7/HHLA2单克隆抗体,由和铂医药Harbour Mice H2L2转基因小鼠平台开发。该项研究结果将以壁报形式在ESMO会议期间进行展示。关于HBM1020 HBM1020是一款由Harbour MiceH2L2转基因小鼠平台开发的靶向B7H7/HHLA2的全球首创全人源单克隆抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4470317_ZH70317_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["L","BK1161","BK4585","BK4107","BK4588","02142","BK1574","LU0053666078.USD","BK1583"],"gpt_icon":0},{"id":"2453752384","title":"和铂医药(02142.HK)预告上半年正面盈利,造血能力持续彰显","url":"https://stock-news.laohu8.com/highlight/detail?id=2453752384","media":"权证网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453752384?lang=zh_cn&edition=full","pubTime":"2024-07-22 17:52","pubTimestamp":1721641929,"startTime":"0","endTime":"0","summary":"和铂医药,一家专注于肿瘤及免疫领域创新抗体疗法发现、开发及商业化的全球生物医药公司,于7月19日率先发布了盈利预告。公告显示,和铂医药2024年上半年录得盈利介乎100万美元至150万美元,而2023年同期盈利约290万美元。值得关注的是,第一,和铂医药是2023年创新药企业年收入5亿元以上的3家录得正面盈利的其中一家;第二,2024年上半年公司继续录得了正面盈利;第三,今年上半年盈利较去年同期有所下滑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072217521395e7e0db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072217521395e7e0db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02142","BK1583","BK1574"],"gpt_icon":0},{"id":"2452412688","title":"港股异动 | 和铂医药-B(02142)盘中跌超6% 预计上半年溢利同比下滑约48.3%至65.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452412688","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452412688?lang=zh_cn&edition=full","pubTime":"2024-07-19 14:38","pubTimestamp":1721371128,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,和铂医药-B(02142)盘中跌超6%,截至发稿,跌4.83%,报1.38港元,成交额195.91万港元。消息面上,和铂医药发布盈警,预期截至2024年6月30日止六个月的溢利将约100万美元至150万美元,上年同期溢利约为290万美元,同比减少约48.3%至65.5%。公告称,预期溢利减少主要归因于收入结构的变动。尤其是期内来自服务业务的收费占总收入的比例较去年上半年的收入有所增加。然而,相较于去年上半年收入中占较大比例的授权收入,该类收入的利润率相对较薄。因此,今年上半年的整体溢利有所减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCEI","BK1583","BK1161","HSTECH","02142","BK1574","YANG"],"gpt_icon":1},{"id":"2452419659","title":"和铂医药-B(02142)下跌5.52%,报1.37元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452419659","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452419659?lang=zh_cn&edition=full","pubTime":"2024-07-19 13:42","pubTimestamp":1721367749,"startTime":"0","endTime":"0","summary":"7月19日,和铂医药-B(02142)盘中下跌5.52%,截至13:42,报1.37元/股,成交148.4万元。和铂医药控股有限公司是一家全球化生物制药企业,专注于肿瘤及免疫性疾病领域的创新药研发及商业化。公司的业务包括自主研发、联合开发创新药物,对外技术授权,以及与全球顶尖学术机构及生物医药公司的创新合作。截至2023年年报,和铂医药-B营业总收入6.34亿元、净利润1.61亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/19134241668404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"2452545419","title":"和铂医药-B盘中异动 股价大跌5.45%报1.371港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452545419","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452545419?lang=zh_cn&edition=full","pubTime":"2024-07-19 13:42","pubTimestamp":1721367747,"startTime":"0","endTime":"0","summary":"2024年07月19日下午盘13时42分,和铂医药-B股票出现异动,股价大幅跳水5.45%。截至发稿,该股报1.371港元/股,成交量104.7万股,换手率0.14%,振幅6.21%。资金方面,该股资金流入45.705万港元,流出96.581万港元。和铂医药-B股票所在的生物技术行业中,整体跌幅为0.52%。其相关个股中,华康生物医学、创胜集团-B、宜明昂科-B涨幅较大,振幅较大的相关个股有华领医药-B、锦欣生殖、盛禾生物-B,振幅分别为17.24%、14.09%、11.60%。因此,报告期间的整体溢利有所减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407191342289681e625&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407191342289681e625&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1574","02142"],"gpt_icon":0},{"id":"2452467990","title":"【公司盈警】和铂医药(02142)料中期溢利减少至100万-150万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452467990","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452467990?lang=zh_cn&edition=full","pubTime":"2024-07-19 08:57","pubTimestamp":1721350652,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和铂医药(02142)公布,预期截至2024年6月30日止6个月的溢利将介乎100万至150万美元,而截至2023年6月30日止6个月的溢利约为290万美元。于报告期间,预期溢利减少乃主要由于收入结构变动所致。尤其是,报告期间来自服务业务的收费占总收入的比例较2023年上半年的收入有所增加。然而,相较于2023年上半年收入中占较大比例的授权收入,此类收入的利润率相对较薄。因此,报告期间的整体溢利有所减少。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZmY3MTQ1MTk1NzQ4ZmYxMDE3ODY4ODUzODA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmY3MTQ1MTk1NzQ4ZmYxMDE3ODY4ODUzODA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1940674","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2452464267","title":"《盈警》和铂医药(02142.HK)料上半年溢利按年减少48.3%至65.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452464267","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452464267?lang=zh_cn&edition=full","pubTime":"2024-07-19 08:13","pubTimestamp":1721347980,"startTime":"0","endTime":"0","summary":"和铂医药发盈警,预期上半年溢利将介乎100万至150万美元,与去年同期溢利约290万美元相比,按年减少约48.3%至65.5%,主要由于收入结构变动所致。尤其是期内来自服务业务的收费占总收入的比例较去年上半年的收入有所增加。然而,相较于去年上半年收入中占较大比例的授权收入,该类收入的利润率相对较薄。因此,今年上半年的整体溢利有所减少。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210504112141597_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210504112141597_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364765/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02142","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2452469564","title":"和铂医药-B发盈警 预计中期溢利约100万美元至150万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452469564","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452469564?lang=zh_cn&edition=full","pubTime":"2024-07-19 07:32","pubTimestamp":1721345522,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)发布公告,预期集团于截至2024年6月30日止六个月的溢利将约100万美元至150万美元,而截至2023年6月30日止六个月的溢利约为290万美元。于报告期间,预期溢利减少主要是由于收入结构变动所致。尤其是,报告期间来自服务业务的收费占总收入的比例较2023年上半年的收入有所增加。然而,相较于2023年上半年收入中占较大比例的授权收入,此类收入的利润率相对较薄。因此,报告期间的整体溢利有所减少。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-19/doc-incermih7948952.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-19/doc-incermih7948952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1574","BK1161","BK1583","02142"],"gpt_icon":0},{"id":"2452329469","title":"和铂医药发布2024年度上半年正面盈利预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2452329469","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452329469?lang=zh_cn&edition=full","pubTime":"2024-07-19 07:15","pubTimestamp":1721344500,"startTime":"0","endTime":"0","summary":"根据对公司报告期内未经审核综合管理帐目的初步审阅,预期上半年盈利约100至150万美元,上年同期盈利约290万美元。报告期内利润预计减少的主要原因是收入结构的变化,具体而言,与2023年上半年相比,报告期内的服务类业务收入在总收入中占比增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4464693_ZH64693_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"2452846601","title":"和铂医药:收入结构变动,预期上半年溢利100万-150万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452846601","media":"界面","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452846601?lang=zh_cn&edition=full","pubTime":"2024-07-19 07:13","pubTimestamp":1721344406,"startTime":"0","endTime":"0","summary":"和铂医药-B7月19日在港交所公告,根据对集团2024上半年未经审计综合管理账目之初步审阅,预期集团于报告期间的溢利将介乎100万美元至150万美元,而2023年上半年的溢利约为290万美元。于报告期间,预期溢利减少乃主要由于收入结构变动所致。尤其是,报告期间来自服务业务的收费占总收入的比例较2023年上半年的收入有所增加。然而,相较于2023年上半年收入中占较大比例的授权收入,此类收入的利润率相对较薄。因此,报告期间的整体溢利有所减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719071326af9304f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719071326af9304f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2452466625","title":"和铂医药-B(02142)发盈警 预计中期溢利约100万美元至150万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452466625","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452466625?lang=zh_cn&edition=full","pubTime":"2024-07-19 07:12","pubTimestamp":1721344335,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和铂医药-B 发布公告,预期集团于截至2024年6月30日止六个月的溢利将约100万美元至150万美元,而截至2023年6月30日止六个月的溢利约为290万美元。于报告期间,预期溢利减少乃主要由于收入结构变动所致。尤其是,报告期间来自服务业务的收费占总收入的比例较2023年上半年的收入有所增加。然而,相较于2023年上半年收入中占较大比例的授权收入,此类收入的利润率相对较薄。因此,报告期间的整体溢利有所减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2452672904","title":"和铂医药-B(02142)上涨5.0%,报1.47元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452672904","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452672904?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:18","pubTimestamp":1721193518,"startTime":"0","endTime":"0","summary":"7月17日,和铂医药-B(02142)盘中上涨5.0%,截至13:18,报1.47元/股,成交125.19万元。和铂医药控股有限公司是一家全球化生物制药企业,专注于肿瘤及免疫性疾病领域的创新药研发及商业化。公司的业务包括自主研发、联合开发创新药物,对外技术授权,以及与全球顶尖学术机构及生物医药公司的创新合作。截至2023年年报,和铂医药-B营业总收入6.34亿元、净利润1.61亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/17131841615538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","02142","BK1583"],"gpt_icon":0},{"id":"2452041149","title":"和铂医药-B盘中异动 下午盘大幅上涨5.00%报1.470港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452041149","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452041149?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:18","pubTimestamp":1721193516,"startTime":"0","endTime":"0","summary":"2024年07月17日下午盘13时18分,和铂医药-B股票出现异动,股价急速拉升5.00%。截至发稿,该股报1.470港元/股,成交量87万股,换手率0.11%,振幅5.00%。资金方面,该股资金流入58.206万港元,流出43.866万港元。和铂医药-B股票所在的生物技术行业中,整体涨幅为1.46%。其相关个股中,百奥赛图-B、昭衍新药、金斯瑞生物科技涨幅较大,振幅较大的相关个股有盛禾生物-B、百奥赛图-B、维亚生物,振幅分别为16.10%、10.89%、9.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407171318369681d78b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407171318369681d78b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","02142","BK1574"],"gpt_icon":0},{"id":"2451693801","title":"港股异动 | 和铂医药-B(02142)涨超3% 双特异性抗体新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2451693801","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451693801?lang=zh_cn&edition=full","pubTime":"2024-07-15 13:35","pubTimestamp":1721021722,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,和铂医药-B(02142)涨超3%,截至发稿,涨3.68%,报1.41港元,成交额103.95万港元。消息面上,7月11日,国家药监局药品审评中心(CDE)官网公示,和铂医药1类新药HBM9027注射液获得临床试验默示许可,拟开发治疗晚期实体瘤。此次HBM9027在中国获批临床,意味着这款新型PD-L1xCD40双特异性抗体即将在中国启动临床研究。今年1月,HBM9027在美国获批临床,和铂医药表示将在美国启动首次人体(FIH)临床试验,评估HBM9027在晚期实体瘤患者中的安全性、耐受性、药代动力学和抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","07226","BK1161","02142","YANG","BK1574","HSCEI","HSTECH"],"gpt_icon":0},{"id":"2450532340","title":"和铂医药(02142)双特异性抗体新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2450532340","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450532340?lang=zh_cn&edition=full","pubTime":"2024-07-12 10:39","pubTimestamp":1720751966,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,7月11日,中国国家药监局药品审评中心官网公示,和铂医药1类新药HBM9027注射液获得临床试验默示许可,拟开发治疗晚期实体瘤。此次HBM9027在中国获批临床,意味着这款新型PD-L1xCD40双特异性抗体即将在中国启动临床研究。今年1月,HBM9027在美国获批临床,和铂医药表示将在美国启动首次人体临床试验,评估HBM9027在晚期实体瘤患者中的安全性、耐受性、药代动力学和抗肿瘤活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1574","02142"],"gpt_icon":0},{"id":"2446404963","title":"和铂医药宣布向国家药品监督管理局重新递交巴托利单抗治疗全身型重症肌无力的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2446404963","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446404963?lang=zh_cn&edition=full","pubTime":"2024-06-27 07:18","pubTimestamp":1719443880,"startTime":"0","endTime":"0","summary":"\" 巴托利单抗于2021年获得中国国家药品监督管理局授予的\"突破性治疗认证\",并于同年8月完成针对中国全身型重症肌无力患者的概念验证研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4448946_ZH48946_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK4123","BK1583","02142","MG","BK1574"],"gpt_icon":0},{"id":"2446344060","title":"和铂医药-B(02142.HK):再次向NMPA提交巴托利单抗(HBM9161)的BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2446344060","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446344060?lang=zh_cn&edition=full","pubTime":"2024-06-27 06:24","pubTimestamp":1719440673,"startTime":"0","endTime":"0","summary":"格隆汇6月27日丨和铂医药-B发布公告,有关开发巴托利单抗的进展。该公告发布后,公司一直与中国国家药品监督管理局就巴托利单抗的生物制品许可申请事宜以及其后提交相关的互动及流程进行积极沟通。公司谨此宣布于2024年6月26日再次向NMPA提交巴托利单抗的BLA。根据披露,巴托利单抗为一种全人源单克隆抗体,其选择性地结合及抑制新生儿FcRn。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062706244595dbb3f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062706244595dbb3f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","BK1161","02142"],"gpt_icon":0},{"id":"2445301470","title":"和铂医药-B盘中异动 大幅上涨5.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445301470","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445301470?lang=zh_cn&edition=full","pubTime":"2024-06-24 13:25","pubTimestamp":1719206758,"startTime":"0","endTime":"0","summary":"2024年06月24日下午盘13时25分,和铂医药-B股票出现异动,股价急速拉升5.63%。和铂医药-B股票所在的生物技术行业中,整体涨幅为0.12%。其相关个股中,康方生物、和铂医药-B、药明生物涨幅较大,振幅较大的相关个股有方达控股、圣诺医药-B、科济药业-B,振幅分别为16.48%、12.27%、9.93%。和铂医药-B公司简介:和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240624132558af8ed3d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240624132558af8ed3d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2445730799","title":"和铂医药-B(02142):Albert R. Collinson获委任为薪酬委员会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2445730799","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445730799?lang=zh_cn&edition=full","pubTime":"2024-06-21 18:53","pubTimestamp":1718967206,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)发布公告,邱家赐已辞任独立非执行董事、董事会审核委员会主...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02142","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2444212501","title":"和铂医药-B(02142)下跌6.02%,报1.25元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2444212501","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444212501?lang=zh_cn&edition=full","pubTime":"2024-06-18 11:28","pubTimestamp":1718681322,"startTime":"0","endTime":"0","summary":"6月18日,和铂医药-B(02142)盘中下跌6.02%,截至11:28,报1.25元/股,成交110.16万元。和铂医药控股有限公司主要从事研究和开发免疫和肿瘤疾病的新型和高度差异化抗体疗法,拥有全球独家权利的和铂抗体平台是其主要技术支持。截至2020年6月30日,该公司已有六个项目进入临床阶段,和铂抗体平台已获得超过45个生物医药行业及学术界合作伙伴的认可。截至2023年年报,和铂医药-B营业总收入6.34亿元、净利润1.61亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061811312995bbe90e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061811312995bbe90e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1574","02142"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.131},{"period":"1month","weight":-0.0667},{"period":"3month","weight":0.008},{"period":"6month","weight":-0.2841},{"period":"1year","weight":-0.2364},{"period":"ytd","weight":-0.3505}],"compareEarnings":[{"period":"1week","weight":-0.0435},{"period":"1month","weight":-0.0591},{"period":"3month","weight":-0.0366},{"period":"6month","weight":0.066},{"period":"1year","weight":-0.1219},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品包括巴托利单抗,主要用于免疫性血小板减少症、甲状腺相关性眼病、重症肌无力、视神经脊髓炎谱系疾病等;以及特那西普,主要用于干眼病。此外,该公司还研究和开发肿瘤免疫产品管线,包括内部开发的新一代肿瘤免疫资产,针对治疗免疫沙漠型、免疫排斥型及炎症型肿瘤。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.111525},{"month":2,"riseRate":0,"avgChangeRate":-0.110405},{"month":3,"riseRate":0.25,"avgChangeRate":-0.124902},{"month":4,"riseRate":0.5,"avgChangeRate":0.027757},{"month":5,"riseRate":0.5,"avgChangeRate":0.040975},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069984},{"month":7,"riseRate":0.25,"avgChangeRate":-0.010915},{"month":8,"riseRate":0,"avgChangeRate":-0.133385},{"month":9,"riseRate":0,"avgChangeRate":-0.201551},{"month":10,"riseRate":0,"avgChangeRate":-0.200739},{"month":11,"riseRate":1,"avgChangeRate":0.440588},{"month":12,"riseRate":0.666667,"avgChangeRate":0.280942}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}